Access to new cancer drugs for children and young adults
Part of Cancer clinical trials.
This trial helps children, teens, and young adults with cancer get early access to promising new drugs that are not yet fully approved for their age group. It collects information on how these drugs work in real-world use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 25 years old or younger
- You have a childhood cancer (solid tumor or leukemia) or a related condition
- You are not currently in another treatment trial
- You are receiving a cancer drug that is either: given as a compassionate use, or an adult cancer drug first approved after 2007 in Europe but not yet approved for children
- Your case has been reviewed by a pediatric cancer expert team (tumor board)
- You or your legal guardian give permission to join
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial helps children, teens, and young adults get an innovative cancer medicine when their disease has returned or hasn’t responded—and standard options are not available. It checks whether a “compassionate use” or off-label medicine plan can be carried out safely for the people who need it.
This study looks at your genes to help doctors choose the safest and most effective cancer medicines for you. It is for children and young adults who are newly diagnosed and about to start treatment.
This early-phase trial studies how safe and effective a combination of four medicines is for children and teens with certain solid tumors that have come back or cannot be controlled with standard treatment. It may help by improving tumor control, while also carefully tracking side effects.
This research study follows young people (babies through age 21) who have been diagnosed with cancer and are currently receiving treatment or in follow-up care. The study aims to better understand their care experiences and outcomes.
This trial studies different treatment plans for children and teens newly diagnosed with AML (a type of blood cancer). Depending on the child's tumor markers and risk group, they may be offered an extra drug (quizartinib) or a targeted antibody (Mylotarg) to see if it improves outcomes.
This study asks children with cancer who are taking new, non-standard medicines to report their symptoms and quality of life. It aims to understand how these treatments affect daily life, even when standard treatments have stopped working.
Hear when a new Pediatric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.